相关实验视频

Updated: Jan 13, 2026

Engineering Antiviral Agents via Surface Plasmon Resonance

Engineering Antiviral Agents via Surface Plasmon Resonance

Published on: June 14, 2022

肝素抗剂的理性设计:基于瓜尼丁的模仿剂揭示了关键的碳水化合物-碳水化合物相互作用

Ankita Chandra¹, Ana Gimeno², María Payá-García³

¹Department of Chemistry, Indian Institute of Science Education and Research, Pune, 411008, India.

European journal of medicinal chemistry

|January 11, 2026

概括

研究人员开发了基于瓜尼丁的新型肝素模仿剂 (HP) 来抵消出血并发症. 这些化合物有效地阻断HP蛋白相互作用,并作为对肝素和 fondaparinux 的强有力的抗毒剂,具有较低的毒性.

科学领域:

药用化学医学化学
碳水化合物化学碳水化合物化学
药理学药理学是指药理学的学科.

背景情况:

肝素 (HP) - 蛋白相互作用在生物过程和血液静止中至关重要.
开发HP蛋白相互作用的抑制剂是治疗出血障碍的关键策略.
现有的抗凝剂,如肝素,需要有效的逆转剂.

研究的目的:

设计和合成新型三糖体氨酸模仿剂,其中包含瓜尼尼残留物.
调查瓜尼丁合并对HP模仿剂结构和生物活性的影响.
评估这些模仿药物作为对肝素和 fondaparinux 的潜在解药.

主要方法:

合理设计和合成八种三糖HP模仿剂与瓜尼尼组.
使用NMR光谱学进行构造分析,以研究结构变化.
在体外评估细胞毒性和抗菌活性.
对抗凝血剂逆转活性对肝素和 fondaparinux 的评估.

主要成果:

瓜尼丁的加入引起了HP模仿物中的显著形状变化.
基于瓜尼丁的模仿药物没有显示抗菌活性和低细胞毒性.
高度取代瓜尼丁的模仿药物作为肝素和 fondaparinux 的亚微分子抗剂.
核磁共振研究证实了碳水化合物与碳水化合物的相互作用,阐明了作用机制.

结论:

新型基于guanidine的HP模仿剂是HP蛋白相互作用的有效抑制剂.
这些化合物代表了对肝素和 fondaparinux 的有希望的新类抗毒剂.
这些发现为调节HP介导的生物功能提供了新的策略.

关键词:

敌对者的敌人敌对者碳水化合物与碳水化合物的相互作用肝素硫酸盐是什么肝素硫酸盐是什么离子相互作用离子相互作用这是一种抗凝血药物.

更多相关视频

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Modification and Functionalization of the Guanidine Group by Tailor-made Precursors

Published on: April 27, 2017

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Using a GFP-tagged TMEM184A Construct for Confirmation of Heparin Receptor Identity

Published on: February 17, 2017

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Drug Binding to Blood Components

Drug Binding to Blood Components

When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...